Acumen Pharmaceuticals, Inc. - 8-K Filing
Acumen Pharmaceuticals reports Q3 2026 net loss of $25.4 million and expects ALTITUDE-AD Phase 2 topline results in November 2026. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $ABOS
Read the full article at SEC EDGAR
Part of the story CBIZ, Inc. - 8-K Filing (3 articles)